2,200 results match your criteria Endometrial Carcinoma* Obstetrics and Gynecology


Effects of RNAi-induced Skp2 inhibition on cell cycle, apoptosis and proliferation of endometrial carcinoma cells.

Exp Ther Med 2019 May 13;17(5):3441-3450. Epub 2019 Mar 13.

Department of Gynecology, Fujian Provincial Maternity and Children's Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China.

The aim of the current study was to investigate the underlying mechanism of S-phase kinase associated protein 2 (Skp2) gene inhibition by lentivirus-mediated RNA interference (RNAi) on the cell cycle, apoptosis and proliferation of endometrial carcinoma HEC-1-A cells. A lentivirus shRNA vector targeting Skp2 was constructed and transfected into HEC-1-A cells. HEC-1-A cells transfected with a scramble sequence were used as negative controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447788PMC
May 2019
1 Read

Clinical presentation of brain metastases from endometrial carcinoma: A case series.

Gynecol Oncol Rep 2019 May 20;28:79-83. Epub 2019 Mar 20.

University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO, United States.

Brain metastases from endometrial carcinoma are rare, however they do occur, and they are associated with an especially poor prognosis. There is evidence demonstrating improved outcomes with early diagnosis and subsequent multimodal treatment. This study therefore aims to review cases of brain metastases from endometrial carcinoma with specific focus on clinical presentation and disease history. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2019.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434091PMC
May 2019
1 Read

Zone Formation of Lymphocyte Infiltration at the Invasive Front Results in the Prolonged Survival of Individuals With Endometrial Serous Carcinoma and Endometrioid Carcinoma With Serous Component.

Anticancer Res 2019 Apr;39(4):2085-2089

Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan.

Background/aim: This study aimed to evaluate the clinical significance of lymphocyte infiltration (LI) for patients with endometrial serous carcinoma and those with endometrioid carcinoma including serous component.

Patients And Methods: Patients who underwent surgery at our hospital between 1990 and 2013 were identified. LI was classified into strong LI, defined as a continuous thick zone of LI, and weak LI, defined as the lack of zone or scattered small foci of LI at the invasive front. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13320DOI Listing
April 2019
2 Reads

Preventive Effects by Black Raspberries of Endometrial Carcinoma Initiation and Promotion Induced by a High-Fat Diet.

Mol Nutr Food Res 2019 Apr 5:e1900013. Epub 2019 Apr 5.

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.

Scope: The chemopreventive effects of black raspberries (BRBs) have not been studied in endometrial tumorigenesis. Here, they are examined in a mouse model of endometrial cancer.

Methods And Results: Wild-type and Pten heterozygous (+/-) female mice are weaned at 3 weeks and fed with four AIN-93G diets: 93G; 93G+5% BRBs powder; high-fat (HF); and HF+5% BRBs. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/mnfr.2019000
Publisher Site
http://dx.doi.org/10.1002/mnfr.201900013DOI Listing
April 2019
1 Read

Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression.

Oncol Lett 2019 May 1;17(5):4575-4589. Epub 2019 Mar 1.

First Pathology Department, Medical School, National Kapodistrian University, Athens 11527, Greece.

Endometrial carcinoma is a common malignancy of the female genital tract. Alterations in the expression levels of various oncogenes and tumor suppressor genes serve important roles in the carcinogenesis and biological behavior of endometrial carcinoma. The aim of the present study was to evaluate the combination and individual expression of p53 and phosphatase and tensin homolog (PTEN) protein in human endometrial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.10093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444490PMC
May 2019
3 Reads

SOX11 hypermethylation as a tumor biomarker in endometrial cancer.

Biochimie 2019 Mar 29;162:8-14. Epub 2019 Mar 29.

Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. Electronic address:

We previously reported that SOX4 is overexpressed in endometrial cancer and that it partially contributes to hypermethylation of miR-129-2 and miR-203. The current study seeks to identify methylation and expression levels of the SOX gene family in endometrial carcinomas. Methylation levels of the 16 SOX gene family members were measured by combining bisulfite restriction analysis (COBRA), MassARRAY, and pyrosequencing assays of cell lines and endometrial cancer samples. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03009084193008
Publisher Site
http://dx.doi.org/10.1016/j.biochi.2019.03.019DOI Listing
March 2019
4 Reads

TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers.

Mod Pathol 2019 Mar 29. Epub 2019 Mar 29.

University of Virginia Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Charlottesville, VA, USA.

The checkpoint molecule TIM-3 is a target for emerging immunotherapies and has been identified on a variety of malignancies. Mismatch repair-deficient endometrial carcinomas have demonstrated durable responses to other checkpoint inhibitors due to high neoantigen loads and robust tumor-associated immune responses. However, little is known about TIM-3 expression in this tumor type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0251-7DOI Listing

IL-6 promotes endometrial cancer cells invasion and migration through signal transducers and activators of transcription 3 signaling pathway.

Pathol Res Pract 2019 Mar 19. Epub 2019 Mar 19.

Reproductive Medicine Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address:

Interleukin (IL)-6 is the most well-known traditional activator of activating signal transducers and activators of transcription 3 (Stat3). They have been proved to promote cancer progression in several human cancers. However, their exact roles in endometrial cancer have not been elucidated clearly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.03.020DOI Listing
March 2019
1 Read

Genome-wide profiling of miRNA expression patterns in tubal endometriosis.

Reproduction 2019 Mar 1. Epub 2019 Mar 1.

J Zhang, Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200030, China.

MicroRNA (miRNA) expression profiles in tubal endometriosis (EM) are still poorly understood. In this study, we analyzed the differential expression of miRNAs and the related gene networks and signaling pathways in tubal EM. Four tubal epithelium samples from tubal EM patients and five normal tubal epithelium samples from uterine leiomyoma patients were collected for miRNA microarray. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/REP-18-0631DOI Listing
March 2019
1 Read
3.174 Impact Factor

Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.

Front Oncol 2019 4;9:123. Epub 2019 Mar 4.

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Endometrial intraepithelial neoplasia (EIN), also known as endometrial atypical hyperplasia (EAH) is believed to be the precursor lesion of endometrioid endometrial carcinoma (EEC). Many genetic factors play important roles in the process of carcinogenesis, however, the key genetic alterations from dysplasia to endometrial cancer remains poorly understood. Germline mutations in Lynch syndrome genes are associated with hereditary endometrial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410638PMC

Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.

Am J Obstet Gynecol 2019 Mar 7. Epub 2019 Mar 7.

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center, New Haven, CT. Electronic address:

Background: Occult uterine cancer at the time of benign hysterectomy poses unique challenges in patient care. There is large variability and uncertainty in estimated risk of occult uterine cancer in the literature and prior research often did not differentiate/include all subtypes.

Objectives: To thoroughly examine the prevalence of occult uterine cancer in a large population-based sample of women undergoing hysterectomy for presumed benign indications and to identify associated risk factors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00029378193043
Publisher Site
http://dx.doi.org/10.1016/j.ajog.2019.02.051DOI Listing
March 2019
5 Reads

Sociodemographic disparities in stage-specific incidences of endometrial cancer: a registry-based study in West Sweden, 1995-2016.

Acta Oncol 2019 Mar 8:1-7. Epub 2019 Mar 8.

e Research and Development, Region Halland , Halmstad , Sweden.

Background: For a few types of cancer, lower socioeconomic status (SES) is associated with higher incidence, and for even more cancer types it is associated with having a less favorable tumor stage at diagnosis. For endometrial cancer (EC), however, there is no clear evidence of such associations with SES. There is a need for analysis of sociodemographic disparities in EC incidences according to stage at diagnosis, which may provide support for trying to improve early detection of EC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1581947DOI Listing
March 2019
1 Read

An Efficacious Endometrial Sampler for Screening Endometrial Cancer.

Front Oncol 2019 19;9:67. Epub 2019 Feb 19.

Center for Single-Cell Biology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.

Recently, the research on early detection of precancerous change and endometrial carcinoma has been focusing on minimally invasive procedures for screening. On this basis, we aim to verify the feasibility of endometrial samplers for screening endometrial cancer using Li Brush. We recruited patients undergoing hysterectomy for different diseases from the Inpatient Department of the Department of Obstetrics and Gynecology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389657PMC
February 2019
2 Reads

The Immunohistochemical Pattern of Epithelial-Mesenchymal Transition Markers In Endometrial Carcinoma.

Appl Immunohistochem Mol Morphol 2019 Feb 28. Epub 2019 Feb 28.

Pathology.

The majority of endometrial carcinoma are diagnosed at an early stage and exhibit a favorable prognosis. However, 10% to 15% of ECs recur and the majority are type II tumors which are high-grade carcinomas. The epithelial-mesenchymal transition (EMT) has been considered as a fundamental step for the development of the invasive phenotype of cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000754DOI Listing
February 2019
3 Reads

Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?

PLoS One 2019 28;14(2):e0211329. Epub 2019 Feb 28.

Department of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa, Israel.

Uterine serous papillary carcinoma (UPSC) is an aggressive tumor, often diagnosed as a metastatic disease and characterized by a high recurrence rate and poor prognosis. UPSC represents a distinct subtype of endometrial cancer which is different in clinical and pathological behaviors from endometrioid endometrial carcinoma (EEC) and resembles more to serous ovarian carcinoma. Since tumors of serous papillary of the ovary are hypothesized to stem from cells of the fallopian tube's fimbria, we hypothesized that UPSC may also origin in the fallopian tubes. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211329PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394988PMC
February 2019
2 Reads

Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line.

J Transl Med 2019 Feb 27;17(1):58. Epub 2019 Feb 27.

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, No. 107 Wenhua Road, Jinan, 250012, Shandong, China.

Background: Progesterone resistance is a problem in endometrial carcinoma, and its underlying molecular mechanisms remain poorly understood. The aim of this study was to elucidate the molecular mechanisms of progesterone resistance and to identify the key genes and pathways mediating progesterone resistance in endometrial cancer using bioinformatics analysis.

Methods: We developed a stable MPA (medroxyprogesterone acetate)-resistant endometrial cancer cell subline named IshikawaPR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1814-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391799PMC
February 2019
1 Read

Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma.

J Pathol Transl Med 2019 Feb 28. Epub 2019 Feb 28.

Obstetrics and Gynecology Department, Faculty of Medicine, Mansoura University, Egypt.

Background: In order to improve the efficacy of endometrial carcinoma (EC) treatment, identifying prognostic factors for high risk patients is a high research priority. This study aimed to assess the relationships among the expression of estrogen receptors (ER), progesterone receptors (PR), HER2, Ki-67, and the different histopathological prognostic parameters in endometrial carcinoma and to assess the value of these in the management of EC.

Materials And Methods: We examined 109 cases of EC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4132/jptm.2019.02.12DOI Listing
February 2019
2 Reads

The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration.

Pathol Oncol Res 2019 Feb 27. Epub 2019 Feb 27.

Departments of Obstetrics and Gynecology, National Defense Medical College Hospital, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.

The aim of this study was to examine the associations among the haphazard invasive patterns, defined as directionless infiltration into the myometrium; expression of key proteins; tumor infiltrative lymphocytes (TILs); and the prognosis of gade-3 endometrioid carcinoma (G3EC). Between 1990 and 2013, patients with G3EC who underwent surgery at our hospital were identified. Invasive patterns were classified into either haphazard, infiltrative, or expansile patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00624-1DOI Listing
February 2019
3 Reads

Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report.

Int J Gynecol Pathol 2019 Feb 21. Epub 2019 Feb 21.

Departments of Pathology (D.B.C., L.L.R., R.R.L.) Obstetrics and Gynecology, Section of Gynecologic Oncology (E.L.), University of Chicago, Chicago, Illinois.

We present an instructive case of FIGO grade 1 endometrioid endometrial carcinoma with a biphasic morphology, corresponding to subclonal loss of mismatch repair proteins (MMRP) MLH1 and PMS2 by immunohistochemistry and subclonal microsatellite instability. A pulmonary metastasis represented only the tumor component with retention of MMRPs. This case illustrates the need for pathologists to recognize and report heterogenous expression of MMRPs in endometrial carcinoma, to consider tumor heterogeneity when selecting foci for molecular studies, and to re-evaluate MMRP expression in tumor metastases, when clinically indicated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000594DOI Listing
February 2019
1 Read

CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding.

Afr Health Sci 2018 Dec;18(4):972-978

Department of Obstetrics and Gynecology, Jawaharlal Institute of Post graduate Medical Education and Research, Puducherry - 605006.

Background: Incidence of endometrial cancer in India is increasing due to lifestyle changes and obesity. As 5 year survival rate of cancer confined to uterus is good, there is need for serum tumor marker for early diagnosis. This study was designed to identify a tumor marker which differentiate endometrial carcinoma and abnormal uterine bleeding (AUB) because common presentation of endometrial carcinoma is AUB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4314/ahs.v18i4.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354887PMC
December 2018
1 Read

Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method.

Arch Gynecol Obstet 2019 May 14;299(5):1373-1384. Epub 2019 Feb 14.

Department of Cardiology, Institute of Mother and Child, Warsaw, Poland.

Purpose: To establish the surgical, demographic and histopathological factors associated with inaccurate sentinel lymph nodes (SLNs) identification using indocyanine green (ICG) and near-infrared (NIR) fluorescence imaging in uterine and cervical neoplasms during both open and laparoscopic surgery.

Methods: We reviewed patients with atypical endometrial hyperplasia (AEH), clinical stage I and II cervical cancer or uterine malignancies who underwent primary surgery with SLN mapping between September 2015 and January 2018. An analysis of patients' demographics, tumor factors and surgical approach was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05063-6DOI Listing
May 2019
1 Read

A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.

Arch Gynecol Obstet 2019 May 12;299(5):1429-1435. Epub 2019 Feb 12.

Medical University of Tianjin, No. 22, Qixiangtai Road, Heping District, Tianjin, China.

Objectives: To determine the feasibility and performance of sentinel lymph-node (SLN) mapping among women with high-risk endometrial cancer (EC).

Materials And Methods: Ninety-eight patients at high-risk EC were enrolled in this retrospective surgical trial from August 2016 to August 2018. All patients underwent intraoperative SLN biopsy, with ICG injection for laparoscopic staging; this was followed by pelvic and paraaortic lymphadenectomy (LAD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05085-0DOI Listing

A case of an endobronchial metastasis from an endometrial carcinoma.

SAGE Open Med Case Rep 2019 16;7:2050313X18823901. Epub 2019 Jan 16.

Department of Pathology, School of Medicine, Dongsan Medical Center, Keimyung University, Daegu, Korea.

A 73-year-old woman was referred to the pulmonology department for abnormal findings on chest computed tomography. She had undergone a laparoscopic staging operation including a hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic node and para-aortic node dissection, and concurrent chemo-radiation therapy for endometrial serous carcinoma stage IIIc cancer 15 months earlier. A follow-up chest computed tomography after the chemotherapy showed that the right lower lobe bronchus was obstructed, and it was necessary to differentiate a primary lung malignancy from a metastasis and secretion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X18823901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349978PMC
January 2019
4 Reads

Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro.

Onco Targets Ther 2019 18;12:685-697. Epub 2019 Jan 18.

Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, People's Republic of China,

Purpose: Our study aimed to investigate the expression of NR1H3 in endometrial carcinoma, its effect on the proliferation of endometrial carcinoma cells in vitro, and the underlying mechanism of this effect.

Materials And Methods: Immunohistochemistry of paraffin-embedded, sectioned specimens and of a tissue microarray was conducted to estimate the expression of NR1H3 (liver X receptors α: LXRα) and NR1H2 (liver X receptors β: LXRβ) in endometrial carcinoma tissues. The subcellular localization of NR1H3 in the endometrial carcinoma cell line Ishikawa was determined by immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S180534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343513PMC
January 2019
4 Reads

Comparison and analysis of the clinicopathological features of SCEO and ECOM.

J Ovarian Res 2019 Jan 30;12(1):10. Epub 2019 Jan 30.

Department of Gynecology, obstetrics and gynecology hospital, Fudan university, Shanghai, 200,090, China.

Objective: The aim of our study was to evaluate and compare the differences in the clinicopathological variables and overall survival (OS) of synchronous primary cancers of the endometrium and ovary (SCEO) and endometrial cancer with ovarian metastasis (ECOM). In addition, we aimed to determine the characteristics of and effective treatments for patients with SCEO to avoid misdiagnosis and overtreatment.

Materials And Methods: A review of medical records from January 2009 to January 2017 revealed 111 patients with coexisting ovarian and endometrial carcinoma diagnosed at the Obstetrics and Gynecology Hospital of Fudan University. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-019-0485-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352368PMC
January 2019
2 Reads

X chromosome-linked long noncoding RNA lnc-XLEC1 regulates c-Myc-dependent cell growth by collaborating with MBP-1 in endometrial cancer.

Int J Cancer 2019 Jan 30. Epub 2019 Jan 30.

Department of Genetics, Medical College of Soochow University, Suzhou, China.

LncRNAs (long noncoding RNAs) are noncoding transcripts that are more than 200 nt long and have been described as the largest subclass in the noncoding transcriptome in humans. Although studies of lncRNAs in cancer have been continuing for a long time, no much has been known about X chromosome-linked lncRNAs. Here, by using RNA-seq we report the identification of a new X chromosome-linked lncRNA (lnc-XLEC1) that is aberrantly downregulated during the development of endometrial carcinoma (EC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32166DOI Listing
January 2019
2 Reads
5.085 Impact Factor

Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases.

Oncol Lett 2019 Feb 20;17(2):2207-2214. Epub 2018 Dec 20.

Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic.

The criteria for distinction between independent primary tumors and metastasis from one site to the other in synchronous endometrioid endometrial and ovarian carcinoma (SEO) has been a matter of dispute for a long time. In our study we performed a comprehensive clinico-pathological and molecular analysis of 22 cases of SEO. Based on conventional clinico-pathological criteria the cases were classified as independent primary tumors (10 cases) and metastasis from one location to the other (12 cases). Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2018.9855
Publisher Site
http://dx.doi.org/10.3892/ol.2018.9855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341770PMC
February 2019
7 Reads

Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.

Gynecol Oncol 2019 Apr 21;153(1):55-62. Epub 2019 Jan 21.

Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China. Electronic address:

Objective: This study aimed to evaluate the efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young patients with endometrial atypical hyperplasia (EAH) and early stage endometrial cancer (EEC) who wished to preserve their fertility.

Methods: Patients with EAH (n = 120) or well-differentiated EEC (n = 40, FIGO stage IA, without myometrial invasion) were retrospectively included. All patients received constant oral progestin combined with hysteroscopic evaluation every 3 months until achieving complete response (CR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.014DOI Listing
April 2019
4 Reads

RE: prognostic factors and genes associated with endometrial cancer based on gene expression profiling and bioinformatics analysis.

Arch Gynecol Obstet 2019 Jan 22. Epub 2019 Jan 22.

Department of Interdisciplinary Program in Biomedical Science, Soonchunhyang University Graduate School, Asan, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05049-4DOI Listing
January 2019

Two-sided role of estrogen on endometrial carcinogenesis: stimulator or suppressor?

Gynecol Endocrinol 2019 Jan 22:1-6. Epub 2019 Jan 22.

a Department of Obstetrics and Gynecology , Shinshu University School of Medicine , Matsumoto , Japan.

Endometrial carcinoma (EC) often expresses estrogen receptors (ER), and the growth of EC is stimulated by estrogen. Therefore, EC is considered to be an estrogen-dependent tumor. However, the role of estrogen in endometrial carcinogenesis is somewhat unclear because the majority of EC occurs at peri- or post menopause when serum estrogen levels are generally decreased. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09513590.2018.1
Publisher Site
http://dx.doi.org/10.1080/09513590.2018.1549219DOI Listing
January 2019
3 Reads

Recurrence of endometrial carcinoma presenting as vulvar lesions.

Int J Gynaecol Obstet 2019 Apr 6;145(1):123-124. Epub 2019 Feb 6.

Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Hebrew University, Jerusalem, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijgo.12762DOI Listing
April 2019
2 Reads

Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis.

BMC Cancer 2019 Jan 15;19(1):73. Epub 2019 Jan 15.

Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, No. 20 Section 3, Renmin South Road, Chengdu, Sichuan, 610041, People's Republic of China.

Background: Several previous studies have confirmed that thrombocytosis was related to reduced survival in many solid tumors. However, the prognostic significance of thrombocytosis in endometrial carcinoma (EC) was still controversy. Therefore, we conducted this study to assess the prognostic value of thrombocytosis in EC. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-5264-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332560PMC
January 2019
12 Reads

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.

PLoS One 2019 15;14(1):e0210585. Epub 2019 Jan 15.

Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

Objective: Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk of recurrence and who may profit from a more aggressive treatment regimen. Our objective was to explore the applicability of plasma growth differentiation factor 15 (GDF-15) as a marker for recurrent disease, as well as a marker for poor prognosis and lymph node metastases.

Methods: EDTA-blood samples were obtained from 235 patients with endometrial cancer before primary surgery. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210585PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333370PMC
January 2019
3 Reads

Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma in young women with hysteroscopic resection and high-dose progesterone therapy.

Taiwan J Obstet Gynecol 2019 Jan;58(1):90-93

Department of Obstetrics and Gynecology, Show Chwan Memorial Hospital, Changhua, Taiwan. Electronic address:

Objective: The standard treatment for endometrial cancer is surgery with hysterectomy. However, this procedure will cause infertility in young women who desire to preserve pregnant ability. Conservative management with hormone therapy has been shown to be satisfactory in both tumor control and fertility preservation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10284559183029
Publisher Site
http://dx.doi.org/10.1016/j.tjog.2018.11.017DOI Listing
January 2019
13 Reads

DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III.

Int J Gynecol Cancer 2019 Jan 13. Epub 2019 Jan 13.

Department of Obstetrics and Gynecology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Objectives: To assess the effects on relative survival of established and new prognostic factors in stage I-III grade 1-3 endometrioid endometrial carcinoma and in the subgroup of stage I grade 1-2.

Methods: This was a population-based, retrospective study including all women (n=1113) in the western Swedish healthcare region diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I-III grade 1-3 endometrioid endometrial carcinoma in 2006-2011. Histology, grade, stage, and age were prospectively reported to the regional clinical and national cancer registers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2018-000082DOI Listing
January 2019

Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease.

Gynecol Oncol 2019 Apr 8;153(1):49-54. Epub 2019 Jan 8.

Department of Obstetrics and Gynecology, University of Tuebingen, Germany.

Objective: Hysterectomy is a frequently used therapeutic option for benign gynecological conditions. The purpose of this study was to investigate the incidence and characteristics of unforeseen malignant pathologies of the uterine corpus in a large population-based, single center cohort.

Methods: Patients who underwent hysterectomy for presumed benign conditions between 2003 and 2016 were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.026DOI Listing
April 2019
3 Reads

The practice of universal screening for Lynch syndrome in newly diagnosed endometrial carcinoma.

Health Sci Rep 2018 Jul 14;1(7):e43. Epub 2018 Jun 14.

Department of Pathology Duke University School of Medicine Durham NC USA.

Background: Lynch syndrome (LS) accounts for 5% of all endometrial cancer (EC) cases and 4% of all lifetime risk of developing colorectal cancer. While current guidelines recommend LS screening for all patients with newly diagnosed colorectal cancer, there is no such guideline for screening patients with EC.

Discussion: This review addresses LS screening and discusses algorithms for testing patients in the setting of newly diagnosed EC. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hsr2.43
Publisher Site
http://dx.doi.org/10.1002/hsr2.43DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266449PMC
July 2018
10 Reads

Prediction of Premalignant and Malignant Endometrial Polyps by Clinical and Hysteroscopic Features.

J Minim Invasive Gynecol 2019 Jan 4. Epub 2019 Jan 4.

Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).. Electronic address:

Study Objective: To investigate whether hysteroscopic features can contribute to the diagnosis of malignancy in endometrial polyps.

Design: Retrospective review.

Setting: Obstetrics and gynecology department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmig.2018.12.018DOI Listing
January 2019
4 Reads

LINC01170 promotes the progression of endometrial carcinoma by activating the AKT pathway.

J BUON 2018 Nov-Dec;23(6):1745-1752

Department of Obstetrics and Gynecology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Purpose: To investigate the function of LINC01170 in the progression of endometrial carcinoma and its underlying mechanism.

Methods: The expression profiles and prognostic data of endometrial carcinoma were downloaded by GDC (genomic data commons) analysis tools. Differentially expressed long noncoding (lnc)RNAs were analyzed by the edgeR (empirical analysis of digital gene expression data in R) package. Read More

View Article

Download full-text PDF

Source
January 2019
12 Reads

Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma.

EBioMedicine 2019 Feb 26;40:276-289. Epub 2018 Dec 26.

The Third School of Clinical Medicine, Southern Medical University, Guangzhou 510500, China; Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University, Shanghai 201499, China. Electronic address:

Background: Endometrial cancer is one of the most common gynecological malignancies and has exhibited an increasing incidence rate in recent years. Cancer stem cells (CSCs), which are responsible for tumor growth and chemoresistance, have been confirmed in endometrial cancer. However, it is still challenging to identify endometrial cancer stem cells to then target for therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964183062
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2018.12.044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412073PMC
February 2019
15 Reads

MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.

BMC Cancer 2018 Dec 29;18(1):1294. Epub 2018 Dec 29.

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, No. 107, Wenhua Xi Road, Jinan, Shandong, 250012, People's Republic of China.

Background: MLH1 plays a critical role in maintaining the fidelity of DNA replication, and defects in human MLH1 have been reported. However, the role of MLH1 in endometrial carcinoma has not been fully investigated. Therefore, we aimed to study the role of MLH1 in the sensitivity of human endometrial carcinoma cells to cisplatin. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-5218-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311060PMC
December 2018
15 Reads

L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.

Anticancer Res 2019 Jan;39(1):421-424

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Aims: In this study, we aimed to investigate how positivity for L1 cell adhesion molecule (L1CAM) was associated with outcome and relapse pattern in patients with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IA-IB endometrial cancer.

Materials And Methods: This retrospective study included 358 patients who underwent surgical treatment for endometrial carcinoma. Tumor samples from 312 patients (87. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13128DOI Listing
January 2019
5 Reads

Upregulation of syncytin-1 promotes invasion and metastasis by activating epithelial-mesenchymal transition-related pathway in endometrial carcinoma.

Onco Targets Ther 2019 17;12:31-40. Epub 2018 Dec 17.

Department of Clinical Medicine Laboratory, Binzhou Medical University Hospital, Binzhou 256603, Shandong, China,

Background: Endometrial carcinoma (EC) is the most common and lethal malignancy worldwide. Syncytin-1 is expressed in multiple types of cancer. However, the expression pattern and potential mechanism of syncytin-1 and its clinical significance in EC remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S191041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301305PMC
December 2018
2 Reads
1.342 Impact Factor

Screening of prognostic biomarkers for endometrial carcinoma based on a ceRNA network.

PeerJ 2018 10;6:e6091. Epub 2018 Dec 10.

Department of Gynaecology and Obstetrics, Shengjing hospital affiliated to China Medical University, Liaoning, China.

Objective: This study aims to reveal the regulation network of lncRNAs-miRNAs-mRNA in endometrial carcinoma (EC), to investigate the underlying mechanisms of EC occurrence and progression, to screen prognostic biomarkers.

Methods: RNA-seq and miRNA-seq data of endometrial carcinoma were downloaded from the TCGA database. Edge. Read More

View Article

Download full-text PDF

Source
https://peerj.com/articles/6091
Publisher Site
http://dx.doi.org/10.7717/peerj.6091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292375PMC
December 2018
18 Reads

miR‑107‑5p promotes tumor proliferation and invasion by targeting estrogen receptor‑α in endometrial carcinoma.

Oncol Rep 2019 Mar 18;41(3):1575-1585. Epub 2018 Dec 18.

Department of Obstetrics and Gynecology, Shanghai General Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China.

The aberrant expression of miR107‑5p is closely related to the development of several types of human cancers. However, the role of miR‑107‑5p in endometrial carcinoma (EC) has not been fully confirmed. In the present study, we aimed to explore the function of miR‑107‑5p in EC carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365687PMC
March 2019
5 Reads
2.191 Impact Factor

L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.

PLoS One 2018 17;13(12):e0209294. Epub 2018 Dec 17.

Department of Pathology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Background: Risk stratification of endometrial carcinomas is primarily based on surgical staging that requires extensive retroperitoneal lymph node dissection. One of the most powerful predictor of lymph node involvement is the lymph vascular space invasion (LVSI). The objective of this study was to determine the potential of L1 Cell Adhesion Molecule (L1CAM) to predict LVSI and its association with other risk factors in endometrioid endometrial carcinomas. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209294PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296540PMC
December 2018

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.

Int J Gynecol Pathol 2019 Jan;38 Suppl 1:S40-S63

Department of Pathology, Memorial Sloan Kettering Cancer Center (R.M., R.A.S.) New York University Medical Center and School of Medicine, Tisch Hospital (K.M.), New York Department of Pathology, University Hospital, Stony Brook School of Medicine, Stony Brook (C.T.), New York Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (B.D.) Department of Pathology, University of California San Diego, San Diego (O.F.) Department of Pathology, Cedars-Sinai Medical Center, Los Angeles (J.K.L.R.), California Department of Pathology, Karolinska Institutet, Stockholm, Sweden (J.A.C.) Department of Pathology, Brigham and Women's Hospital, Harvard Medical School (C.P.C.) Department of Pathology, Massachussetts General Hospital, Harvard Medical School (E.O.), Boston, Massachussetts Department of Pathology, University of British Columbia, Vancouver (C.B.G., J.A.I.) Department of Laboratory Medicine, Pathology and Medical Genetics, Royal Jubilee Hospital, Victoria (J.A.I.), BC, Canada Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas (A.M.) Department of Pathology, Hospital University Arnau de Vilanova; and Department of Pathology, Hospital University de Bellvitge, IRBLLEIDA, IDIBELL, University of Lleida, CIBERONC, Barcelona, Spain (X.M.-G.) Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK (W.G.M.) Department of Pathology and Obstetrics and Gynecology, Yale School of Medicine and Yale School of Publich Health, New Haven, Connecticut (V.P.) Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland (P.N.S.) Department of Pathology, KEMH and School for Women's and Infants' Health, University of Western Australia, Perth, WA, Australia (C.J.R.S.).

This review of challenging diagnostic issues concerning high-grade endometrial carcinomas is derived from the authors' review of the literature followed by discussions at the Endometrial Cancer Workshop sponsored by the International Society of Gynecological Pathologists in 2016. Recommendations presented are evidence-based, insofar as this is possible, given that the levels of evidence are weak or moderate due to small sample sizes and nonuniform diagnostic criteria used in many studies. High-grade endometrioid carcinomas include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated carcinomas, and carcinosarcomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296248PMC
January 2019
33 Reads

Current Practices in the Processing, Diagnosis, and Reporting of Endometrial Carcinoma: Results of a Web-based Survey by the International Society of Gynecological Pathologists (ISGyP).

Int J Gynecol Pathol 2019 Jan;38 Suppl 1:S3-S8

Department of Pathology and Obstetrics and Gynecology, Yale School of Medicine and the Yale School of Public Health, New Haven, Connecticut (V.P.) Department of Pathology, Hospital University Arnau de Vilanova and University de Bellvitge, Irblleida, Idibell, University of Lleida, Ciberonc, Lleida, Spain (X.M.G.) Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (E.O.) Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.M.) Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK (W.G.M.).

There have been significant advances in our understanding of the biology and classification of endometrial carcinoma, over the last few years, and the new prediction models proposed for prognostication. To accurately diagnose and stage tumors and apply these prediction models, it is necessary that there be standardized processing of specimens, and a common understanding and usage of the diagnostic terminology of endometrial carcinoma. The International Society of Gynecological Pathologists embarked on an ambitious project to achieve this goal in 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296828PMC
January 2019

The International Society of Gynecological Pathologists (ISGyP) Endometrial Carcinoma Project.

Int J Gynecol Pathol 2019 Jan;38 Suppl 1:S1-S2

Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK (W.G.M.) Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.M.) Departments of Pathology, Hospital University Arnau de Vilanova and, Hospital University de Bellvitge, IRBLLEIDA, Idibell, University of Lleida, CIBERONC, Barcelona, Spain (X.M.-G.) James Homer Wright Pathology Laboratories, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts (E.O.) Department of Pathology and Obstetrics and Gynecology, Yale School of Medicine and Yale School of Public Health, New Haven, Connecticut (V.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296830PMC
January 2019

Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer.

Cureus 2018 Sep 29;10(9):e3387. Epub 2018 Sep 29.

Radiation Oncology, Juravinski Cancer Centre-McMaster University, Hamilton, CAN.

Purpose: Serous adenocarcinoma is a rare, aggressive histologic subtype of endometrial cancer with a high rate of recurrence and a poor prognosis. The optimal adjuvant treatment for early-stage patients is unclear. Our objective was to evaluate the outcomes of stage IA serous endometrial cancers only treated at a single institution and determine whether our current approach of chemotherapy plus vaginal brachytherapy (VBT) is sufficient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267614PMC
September 2018
4 Reads